{
    "nct_id": "NCT06438588",
    "official_title": "Effect of Fasting Mimicking Diet (FMD) on Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors: the FMD-ICI Feasibility Pilot Study",
    "inclusion_criteria": "* Patients undergoing immunotherapy for their first time\n* Age â‰¥ 18 years\n* Body mass index (BMI) > 19\n* Histological confirmation of advanced stage malignancies (stage 3 or 4) appropriate for the following types of immunotherapy: PD-1 antibody (nivolumab, pembrolizumab), PD-L1 antibody (atezolizumab, avelumab, durvalumab), CTLA-4 antibody (ipilimumab) or any combination thereof\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Age < 18 years\n* Pregnant women\n* Nursing mothers\n* Persons of childbearing potential who are unwilling to employ adequate contraception\n* Patients will be excluded if they are on insulin due to diabetes (diabetic patients will be asked to monitor their glucose levels with a continuous glucose monitoring [CGM] device), if they have allergies to any of the components in the FMD, if there is unacceptable deterioration of their nutritional status and cancer progression",
    "miscellaneous_criteria": ""
}